AMD Awareness

Companies announce eye care collaboration

AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.

Early Phase 2 data with high-dose aflibercept promising in wet AMD

Regeneron Pharmaceuticals announced at an ongoing Phase 2 trial has met its primary safety endpoint with no new safety signals observed.

Wet AMD: Current therapies and treatment

Experts discuss durability of action and atrophy inhibitor among primary treatment goals.